Sign in
WithdrawnNo phase

Stereotactic Ablative Radiotherapy (SAbR) for Treatment of Ventricular Tachycardia (VT) Refractory Standard Invasive Ablation Techniques

Key facts

Who runs it
University of Texas Southwestern Medical Center
Where
Dallas, United StatesSee the site
Trial code
Status
Withdrawn
Started
Feb 2023
Ended
1 Mar 2025
Type of study
Interventional
Treatments tested
  • Stereotactic ablative radiotherapy
Record updated
17 August 2022
Why it stopped
The study was stopped due to participation in a multi-center randomized controlled trial with competing enrollment criteria.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Have an ICD implanted > 6 months and all VT episodes in the past 6 months are available in device memory
  • Within the past 3 months, the patient has at least one episode of symptomatic monomorphic VT that requires ICD treatment (anti-tachycardia pacing and/or ICD shock) or was sustained/incessant but falls under ICD treatment zone. These VT episodes must occur after at least one standard invasive VT ablation or occur in a patient that is clinically deemed not eligible to the standard VT ablation procedure
  • Two independent cardiac electrophysiologists reviewed the case and agreed that the patient would benefit from suppression of these VT episodes but there is no optimal invasive VT ablation or antiarrhythmic drug options

Who cannot take part

  • On potent immunosuppressive therapy (e.g., post organ transplant)
  • Has severe co-morbid medical condition or terminal illness and is unlikely to survive more than 6 months regardless of VT status based on clinical judgement by treating or enrolling physicians
  • Has severe collagen vascular disorder with organ involvement
  • Has contraindication to receive SAbR or VT clinically deemed not suitable for SAbR
  • Is pregnant
  • Not willing or not able to consent to participate in the study

Where in United States

  • University of Texas Southwestern Medical Center - DallasDallas, United States

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the clinical efficacy and safety of stereotactic ablative radiotherapy (SAbR), also known as stereotactic body radiation therapy (SBRT), for treatment of ventricular tachycardia (VT) requiring implantable cardioverter defibrillator (ICD) treatments in patients with VT refractory to standard invasive ablation techniques. We hypothesized that SAbR is effective in suppressing sustained VT and reducing ICD treatments in this group of patients and is associated with acceptably low risk of serious complications.

The group in the trial

  • ArmOther group

    No arm

    Treatment: Stereotactic ablative radiotherapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
17 August 2022